Abstract
Hutchinson–Gilford progeria syndrome (HGPS), commonly called progeria, is an extremely rare disorder that affects only one child per four million births. It is characterized by accelerated aging in affected individuals leading to premature death at an average age of 14.5 years due to cardiovascular complications. The main cause of HGPS is a sporadic autosomal dominant point mutation in LMNA gene resulting in differently spliced lamin A protein known as progerin. Accumulation of progerin under nuclear lamina and activation of its downstream effectors cause perturbation in cellular morphology and physiology which leads to a systemic disorder that mainly impairs the cardiovascular system, bones, skin, and overall growth. Till now, no cure has been found for this catastrophic disorder; however, several therapeutic strategies are under development. The current review focuses on the overall progress in the field of therapeutic approaches for the management/cure of HGPS. We have also discussed the new disease models that have been developed for the study of this rare disorder. Moreover, we have highlighted the therapeutic application of extracellular vesicles derived from stem cells against aging and aging-related disorders and, therefore, suggest the same for the treatment of HGPS.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abdenur JE, Brown WT, Friedman S, Smith M, Lifshitz F (1997) Response to nutritional and growth hormone treatment in progeria. Metab Clin Exp 46:851–856. https://doi.org/10.1016/S0026-0495(97)90069-X
Adamiak M, Cheng G, Bobis-Wozowicz S, Zhao L, Kedracka-Krok S, Samanta A, Karnas E, Xuan YT, Skupien-Rabian B, Chen X, Jankowska U, Girgis M, Sekula M, Davani A, Lasota S, Vincent RJ, Sarna M, Newell KL, Wang OL, Dudley N, Madeja Z, Dawn B, Zuba-Surma EK (2018) Induced pluripotent stem cell (iPSC)-derived extracellular vesicles are safer and more effective for cardiac repair than iPSCs. Circ Res 122:296–309. https://doi.org/10.1161/CIRCRESAHA.117.311769
Adler AS, Sinha S, Kawahara TLA, Zhang JY, Segal E, Chang HY (2007) Motif module map reveals enforcement of aging by continual NF-kappaB activity. Genes Dev 21:3244–3257. https://doi.org/10.1101/gad.1588507
Alibhai FJ, Tobin SW, Yeganeh A, Weisel RD, Li R-K (2018) Emerging roles of extracellular vesicles in cardiac repair and rejuvenation. Am J Phys Heart Circ Phys 315:H733–H744. https://doi.org/10.1152/ajpheart.00100.2018
Aliper AM, Csoka AB, Buzdin A, Jetka T, Roumiantsev S, Moskalev A, Zhavoronkov A (2015) Signaling pathway activation drift during aging: Hutchinson-Gilford progeria syndrome fibroblasts are comparable to normal middle-age and old-age cells. Aging 7:26–37. https://doi.org/10.18632/aging.100717
Ao Y et al (2019) Lamin A buffers CK2 kinase activity to modulate aging in a progeria mouse model. Sci Adv 5:eaav5078–eaav5078. https://doi.org/10.1126/sciadv.aav5078
Arancio W, Genovese SI, Pizzolanti G, Giordano C (2015) Hutchinson Gilford progeria syndrome: a therapeutic approach via adenoviral delivery of CRISPR/cas genome editing system. J Genet Syndr Gene Ther 6:1. https://doi.org/10.4172/2157-7412.1000256
Atchison L, Zhang H, Cao K, Truskey GA (2017) A tissue engineered blood vessel model of Hutchinson-Gilford progeria syndrome using human iPSC-derived smooth muscle cells. Sci Rep 7:8168. https://doi.org/10.1038/s41598-017-08632-4
Augert A, Payré C, de Launoit Y, Gil J, Lambeau G, Bernard D (2009) The M-type receptor PLA2R regulates senescence through the p53 pathway. EMBO Rep 10:271–277. https://doi.org/10.1038/embor.2008.255
Baar MP et al (2017) Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 169:132–147.e116. https://doi.org/10.1016/j.cell.2017.02.031
Balmus G et al (2018) Targeting of NAT10 enhances healthspan in a mouse model of human accelerated aging syndrome. Nat Commun 9:1700. https://doi.org/10.1038/s41467-018-03770-3
Bárcena C et al (2018) Methionine restriction extends lifespan in progeroid mice and alters lipid and bile acid metabolism. Cell Rep 24:2392–2403. https://doi.org/10.1016/j.celrep.2018.07.089
Bárcena C, López-Otín C, Kroemer G (2019a) Methionine restriction for improving progeria: another autophagy-inducing anti-aging strategy? Autophagy 15:558–559. https://doi.org/10.1080/15548627.2018.1533059
Bárcena C et al (2019b) Healthspan and lifespan extension by fecal microbiota transplantation into progeroid mice. Nat Med 25:1234–1242. https://doi.org/10.1038/s41591-019-0504-5
Barthélémy F et al (2015) Truncated prelamin A expression in HGPS-like patients: a transcriptional study. Eur J Hum Genet 23:1051–1061. https://doi.org/10.1038/ejhg.2014.239
Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA (2016) Metformin as a tool to target aging. Cell Metab 23:1060–1065. https://doi.org/10.1016/j.cmet.2016.05.011
Bergo MO et al (2002) Zmpste24 deficiency in mice causes spontaneous bone fractures, muscle weakness, and a prelamin A processing defect. Proc Natl Acad Sci U S A 99:13049–13054. https://doi.org/10.1073/pnas.192460799
Beyret E et al (2019) Single-dose CRISPR–Cas9 therapy extends lifespan of mice with Hutchinson–Gilford progeria syndrome. Nat Med 25:419–422. https://doi.org/10.1038/s41591-019-0343-4
Bikkul MU, Clements CS, Godwin LS, Goldberg MW, Kill IR, Bridger JM (2018) Farnesyltransferase inhibitor and rapamycin correct aberrant genome organisation and decrease DNA damage respectively, in Hutchinson-Gilford progeria syndrome fibroblasts. Biogerontology 19:579–602. https://doi.org/10.1007/s10522-018-9758-4
Bjedov I, Toivonen JM, Kerr F, Slack C, Jacobson J, Foley A, Partridge L (2010) Mechanisms of life span extension by rapamycin in the fruit fly Drosophila melanogaster. Cell Metab 11:35–46. https://doi.org/10.1016/j.cmet.2009.11.010
Blondel S et al (2014) Induced pluripotent stem cells reveal functional differences between drugs currently investigated in patients with Hutchinson-Gilford progeria syndrome. Stem Cells Transl Med 3:510–519. https://doi.org/10.5966/sctm.2013-0168
Blondel S et al (2016) Drug screening on Hutchinson Gilford progeria pluripotent stem cells reveals aminopyrimidines as new modulators of farnesylation. Cell Death Dis 7:e2105–e2105. https://doi.org/10.1038/cddis.2015.374
Bridger JM, Kill IR (2004) Aging of Hutchinson–Gilford progeria syndrome fibroblasts is characterised by hyperproliferation and increased apoptosis. Exp Gerontol 39:717–724. https://doi.org/10.1016/j.exger.2004.02.002
Cao K, Graziotto JJ, Blair CD, Mazzulli JR, Erdos MR, Krainc D, Collins FS (2011) Rapamycin reverses cellular phenotypes and enhances mutant protein clearance in Hutchinson-Gilford progeria syndrome cells. Sci Transl Med 3:89ra58. https://doi.org/10.1126/scitranslmed.3002346
Capell BC et al (2005) Inhibiting farnesylation of progerin prevents the characteristic nuclear blebbing of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 102:12879–12884. https://doi.org/10.1073/pnas.0506001102
Capell BC et al (2008) A farnesyltransferase inhibitor prevents both the onset and late progression of cardiovascular disease in a progeria mouse model. Proc Natl Acad Sci U S A 105:15902–15907. https://doi.org/10.1073/pnas.0807840105
Carrero D, Soria-Valles C, López-Otín C (2016) Hallmarks of progeroid syndromes: lessons from mice and reprogrammed cells. Dis Model Mech 9:719–735. https://doi.org/10.1242/dmm.024711
Cenni V et al (2011) Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria. Eur J Histochem: EJH 55:e36–e36. https://doi.org/10.4081/ejh.2011.e36
Chang J et al (2016) Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22:78–83. https://doi.org/10.1038/nm.4010
Chang W, Wang Y, Luxton GWG, Östlund C, Worman HJ, Gundersen GG (2019) Imbalanced nucleocytoskeletal connections create common polarity defects in progeria and physiological aging. Proc Natl Acad Sci 116:3578. https://doi.org/10.1073/pnas.1809683116
Charlesworth CT et al (2019) Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med 25:249–254. https://doi.org/10.1038/s41591-018-0326-x
Chen Z-J et al (2014) Dysregulated interactions between lamin A and SUN1 induce abnormalities in the nuclear envelope and endoplasmic reticulum in progeric laminopathies. J Cell Sci 127:1792. https://doi.org/10.1242/jcs.139683
Chen Z et al (2017) Reprogramming progeria fibroblasts re-establishes a normal epigenetic landscape. Aging Cell 16:870–887. https://doi.org/10.1111/acel.12621
Chen C-Y et al (2018) Exosomal DMBT1 from human urine-derived stem cells facilitates diabetic wound repair by promoting angiogenesis. Theranostics 8:1607–1623. https://doi.org/10.7150/thno.22958
Chen C-Y et al (2019) Extracellular vesicles from human urine-derived stem cells prevent osteoporosis by transferring CTHRC1 and OPG. Bone Res 7:18–18. https://doi.org/10.1038/s41413-019-0056-9
Cheng R et al (2014) Efficient gene editing in adult mouse livers via adenoviral delivery of CRISPR/Cas9. FEBS Lett 588:3954–3958. https://doi.org/10.1016/j.febslet.2014.09.008
Chiang PK, Gordon RK, Tal J, Zeng GC, Doctor BP, Pardhasaradhi K, McCann PP (1996) S-Adenosylmethionine and methylation. FASEB J 10:471–480. https://doi.org/10.1096/fasebj.10.4.8647346
Chu C, Wei S, Wang Y, Wang Y, Man Y, Qu Y (2019) Extracellular vesicle and mesenchymal stem cells in bone regeneration: recent progress and perspectives. J Biomed Mater Res A 107:243–250. https://doi.org/10.1002/jbm.a.36518
Chueh S-CJ, Kahan BD (2005) Clinical application of sirolimus in renal transplantation: an update. Transpl Int 18:261–277. https://doi.org/10.1111/j.1432-2277.2004.00039.x
Coffinier C et al (2010) Direct synthesis of lamin A, bypassing prelamin a processing, causes misshapen nuclei in fibroblasts but no detectable pathology in mice. J Biol Chem 285:20818–20826. https://doi.org/10.1074/jbc.M110.128835
Columbaro M et al (2005) Rescue of heterochromatin organization in Hutchinson-Gilford progeria by drug treatment. Cellular and Molecular Life Sciences : CMLS 62:2669–2678. https://doi.org/10.1007/s00018-005-5318-6
Compagnucci C, Bertini E (2017) The potential of iPSCs for the treatment of premature aging disorders. Int J Mol Sci 18:2350. https://doi.org/10.3390/ijms18112350
Constantinescu D, Csoka AB, Navara CS, Schatten GP (2010) Defective DSB repair correlates with abnormal nuclear morphology and is improved with FTI treatment in Hutchinson-Gilford progeria syndrome fibroblasts. Exp Cell Res 316:2747–2759. https://doi.org/10.1016/j.yexcr.2010.05.015
Csoka AB et al (2004) Genome-scale expression profiling of Hutchinson–Gilford progeria syndrome reveals widespread transcriptional misregulation leading to mesodermal/mesenchymal defects and accelerated atherosclerosis. Aging Cell 3:235–243. https://doi.org/10.1111/j.1474-9728.2004.00105.x
Dahl KN, Scaffidi P, Islam MF, Yodh AG, Wilson KL, Misteli T (2006) Distinct structural and mechanical properties of the nuclear lamina in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 103:10271–10276. https://doi.org/10.1073/pnas.0601058103
de la Rosa J et al (2013) Prelamin A causes progeria through cell-extrinsic mechanisms and prevents cancer invasion. Nat Commun 4:2268–2268. https://doi.org/10.1038/ncomms3268
De Sandre-Giovannoli A et al (2003) Lamin a truncation in Hutchinson-Gilford progeria. Science 300:2055. https://doi.org/10.1126/science.1084125
De Vos WH et al (2010) Increased plasticity of the nuclear envelope and hypermobility of telomeres due to the loss of A–type lamins. Biochim Biophys Acta Gen Subj 1800:448–458. https://doi.org/10.1016/j.bbagen.2010.01.002
Decker ML, Chavez E, Vulto I, Lansdorp PM (2009) Telomere length in Hutchinson-Gilford progeria syndrome. Mech Ageing Dev 130:377–383. https://doi.org/10.1016/j.mad.2009.03.001
del Campo L et al (2019) Vascular smooth muscle cell-specific progerin expression in a mouse model of Hutchinson–Gilford progeria syndrome promotes arterial stiffness: therapeutic effect of dietary nitrite. Aging Cell 18:e12936. https://doi.org/10.1111/acel.12936
Ding Q et al (2014) Permanent alteration of PCSK9 with in vivo CRISPR-Cas9 genome editing. Circ Res 115:488–492. https://doi.org/10.1161/CIRCRESAHA.115.304351
Domingo DL et al (2009) Hutchinson-Gilford progeria syndrome: oral and craniofacial phenotypes. Oral Dis 15:187–195. https://doi.org/10.1111/j.1601-0825.2009.01521.x
Dorado B et al (2019) Generation and characterization of a novel knockin minipig model of Hutchinson-Gilford progeria syndrome. Cell Discovery 5:16. https://doi.org/10.1038/s41421-019-0084-z
Doubaj Y et al (2012) An inherited LMNA gene mutation in atypical progeria syndrome. Am J Med Genet A 158A:2881–2887. https://doi.org/10.1002/ajmg.a.35557
DuBose AJ, Lichtenstein ST, Petrash NM, Erdos MR, Gordon LB, Collins FS (2018) Everolimus rescues multiple cellular defects in laminopathy-patient fibroblasts. Proc Natl Acad Sci U S A 115:4206–4211. https://doi.org/10.1073/pnas.1802811115
Egesipe A-L et al (2016) Metformin decreases progerin expression and alleviates pathological defects of Hutchinson–Gilford progeria syndrome cells. NPJ Aging Mech Dis 2:16026. https://doi.org/10.1038/npjamd.2016.26 https://www.nature.com/articles/npjamd201626#supplementary-information
Ehninger D, Neff F, Xie K (2014) Longevity, aging and rapamycin. Cell Mol Life Sci: CMLS 71:4325–4346. https://doi.org/10.1007/s00018-014-1677-1
Elloso MM et al (2003) Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in Apo E-deficient mice. Am J Transplant 3:562–569. https://doi.org/10.1034/j.1600-6143.2003.00094.x
Eriksson M et al (2003) Recurrent de novo point mutations in lamin A cause Hutchinson–Gilford progeria syndrome. Nature 423:293–298. https://doi.org/10.1038/nature01629
Espandar R, Eraghi AS, Mardookhpour S (2012) Simultaneous shoulder and hip dislocation in a 12-year-old girl with Hutchinson-Gilford progeria syndrome. Acta Medica Iranica 50:439–443
Evangelisti C, Cenni V, Lattanzi G (2016) Potential therapeutic effects of the MTOR inhibitors for preventing ageing and progeria-related disorders. Br J Clin Pharmacol 82:1229–1244. https://doi.org/10.1111/bcp.12928
Ferreira AF, Gomes DA (2018) Stem cell extracellular vesicles in skin repair. Bioengineering 6:4. https://doi.org/10.3390/bioengineering6010004
Finley J (2018) Cellular stress and AMPK activation as a common mechanism of action linking the effects of metformin and diverse compounds that alleviate accelerated aging defects in Hutchinson-Gilford progeria syndrome. Med Hypotheses 118:151–162. https://doi.org/10.1016/j.mehy.2018.06.029
Fong LG et al (2004) Heterozygosity for Lmna deficiency eliminates the progeria-like phenotypes in Zmpste24-deficient mice. Proc Natl Acad Sci U S A 101:18111–18116. https://doi.org/10.1073/pnas.0408558102
Fong LG, Frost D, Meta M, Qiao X, Yang SH, Coffinier C, Young SG (2006a) A protein farnesyltransferase inhibitor ameliorates disease in a mouse model of progeria. Science 311:1621. https://doi.org/10.1126/science.1124875
Fong LG et al (2006b) Prelamin A and lamin A appear to be dispensable in the nuclear lamina. J Clin Invest 116:743–752. https://doi.org/10.1172/JCI27125
Frankel D, Delecourt V, Harhouri K, De Sandre-Giovannoli A, Lévy N, Kaspi E, Roll P (2018) MicroRNAs in hereditary and sporadic premature aging syndromes and other laminopathies. Aging Cell 17:e12766–e12766. https://doi.org/10.1111/acel.12766
Gabriel D, Roedl D, Gordon LB, Djabali K (2015) Sulforaphane enhances progerin clearance in Hutchinson-Gilford progeria fibroblasts. Aging Cell 14:78–91. https://doi.org/10.1111/acel.12300
Gabriel D, Gordon LB, Djabali K (2016) Temsirolimus partially rescues the Hutchinson-Gilford progeria cellular phenotype. PLoS One 11:e0168988–e0168988. https://doi.org/10.1371/journal.pone.0168988
Gabriel D, Shafry DD, Gordon LB, Djabali K (2017) Intermittent treatment with farnesyltransferase inhibitor and sulforaphane improves cellular homeostasis in Hutchinson-Gilford progeria fibroblasts. Oncotarget 8:64809–64826. https://doi.org/10.18632/oncotarget.19363
García-Aguirre I et al (2019) Enhanced nuclear protein export in premature aging and rescue of the progeria phenotype by modulation of CRM1 activity. Aging Cell 18:e13002. https://doi.org/10.1111/acel.13002
Geng L et al (2018) Chemical screen identifies a geroprotective role of quercetin in premature aging. Protein & Cell 10:417–435. https://doi.org/10.1007/s13238-018-0567-y
Georgescu A, Alexandru N, Andrei E, Dragan E, Cochior D, Dias S (2016) Effects of transplanted circulating endothelial progenitor cells and platelet microparticles in atherosclerosis development. Biol Cell 108:219–243. https://doi.org/10.1111/boc.201500104
Georgescu A, Alexandru N, Dragan E, Safciuc F, Daraban AM, Badila E (2017) Endothelial progenitor cells - derived microparticles reproduce the favorable role of their parent cells of healthy origins in the treatment of atherosclerosis via microrna transfer. Atherosclerosis 263:e48. https://doi.org/10.1016/j.atherosclerosis.2017.06.163
Gesson K, Rescheneder P, Skoruppa MP, von Haeseler A, Dechat T, Foisner R (2016) A-type lamins bind both hetero- and euchromatin, the latter being regulated by lamina-associated polypeptide 2 alpha. Genome Res 26:462–473. https://doi.org/10.1101/gr.196220.115
Ghanemi A (2015) Cell cultures in drug development: applications, challenges and limitations. Saudi Pharm J 23:453–454. https://doi.org/10.1016/j.jsps.2014.04.002
Ghosh S, Zhou Z (2014) Genetics of aging, progeria and lamin disorders. Curr Opin Genet Dev 26:41–46. https://doi.org/10.1016/j.gde.2014.05.003
Glynn MW, Glover TW (2005) Incomplete processing of mutant lamin A in Hutchinson–Gilford progeria leads to nuclear abnormalities, which are reversed by farnesyltransferase inhibition. Hum Mol Genet 14:2959–2969. https://doi.org/10.1093/hmg/ddi326
Goldman RD et al (2004) Accumulation of mutant lamin A causes progressive changes in nuclear architecture in Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 101:8963–8968. https://doi.org/10.1073/pnas.0402943101
Gonzalez-Suarez I et al (2009) Novel roles for A-type lamins in telomere biology and the DNA damage response pathway. EMBO J 28:2414–2427. https://doi.org/10.1038/emboj.2009.196
Gonzalo S, Kreienkamp R (2015) DNA repair defects and genome instability in Hutchinson-Gilford progeria syndrome. Curr Opin Cell Biol 34:75–83. https://doi.org/10.1016/j.ceb.2015.05.007
Gordon LB (2019a) Clinical trials. The Progeria Research Foundation https://www.progeriaresearch.org/clinical-trials/.
Gordon LB (2019b) Find the children. Progeria Research Foundation https://www.progeriaresearch.org/find-the-children/.
Gordon LB (2019c) The progeria handbook: a guide for families & health care providers of children with progeria. Progeria Research Foundation, Peabody, MA
Gordon LB (2019d) The Progeria Research Foundation Cell and Tissue Bank. Progeria Research Foundation https://www.progeriaresearch.org/wp-content/uploads/2019/11/PRF-AVAILABLE-CELL-LINES-1.pdf.
Gordon LB, Brown WT, Collins FS (2003) Hutchinson-Gilford progeria syndrome. University of Washington. https://www.ncbi.nlm.nih.gov/books/NBK1121/ Accessed 03 April 2019 2019
Gordon LB, McCarten KM, Giobbie-Hurder A, Machan JT, Campbell SE, Berns SD, Kieran MW (2007) Disease progression in Hutchinson-Gilford progeria syndrome: impact on growth and development. Pediatrics 120:824. https://doi.org/10.1542/peds.2007-1357
Gordon LB, Cao K, Collins FS (2012a) Progeria: translational insights from cell biology. J Cell Biol 199:9–13. https://doi.org/10.1083/jcb.201207072
Gordon LB et al (2012b) Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 109:16666–16671. https://doi.org/10.1073/pnas.1202529109
Gordon LB et al (2014) Impact of farnesylation inhibitors on survival in Hutchinson-Gilford progeria syndrome. Circulation 130:27–34. https://doi.org/10.1161/CIRCULATIONAHA.113.008285
Gordon LB et al (2016) Clinical trial of the protein farnesylation inhibitors lonafarnib, pravastatin, and zoledronic acid in children with Hutchinson-Gilford progeria syndrome. Circulation 134:114–125. https://doi.org/10.1161/CIRCULATIONAHA.116.022188
Gordon LB et al (2018) Association of lonafarnib treatment vs no treatment with mortality rate in patients with Hutchinson-Gilford progeria syndrome. JAMA 319:1687–1695. https://doi.org/10.1001/jama.2018.3264
Gordon CM et al (2019) Extraskeletal calcifications in Hutchinson-Gilford progeria syndrome. Bone 125:103–111. https://doi.org/10.1016/j.bone.2019.05.008
Griveau A et al (2016) The PLA2R1-JAK2 pathway upregulates ERRα and its mitochondrial program to exert tumor-suppressive action. Oncogene 35:5033. https://doi.org/10.1038/onc.2016.43 https://www.nature.com/articles/onc201643#supplementary-information
Griveau A et al (2018) Targeting the phospholipase A2 receptor ameliorates premature aging phenotypes. Aging Cell 17:e12835–e12835. https://doi.org/10.1111/acel.12835
Guardiani E et al (2011) Otologic and audiologic manifestations of Hutchinson-Gilford progeria syndrome. Laryngoscope 121:2250–2255. https://doi.org/10.1002/lary.22151
Gulei D, Berindan-Neagoe I (2019) Activation of necroptosis by engineered self tumor-derived exosomes loaded with CRISPR/Cas9. Mol Ther Nucleic Acids 17:448–451. https://doi.org/10.1016/j.omtn.2019.05.032
Gustavo Monnerat GPCE, Evaristo JAM, dos Santos CGM, Maciel GCL, Carvalho VO, Nogueira FCS, Domont GB, de Carvalho ACC (2019) Metabolomic profiling suggests systemic signatures of premature aging induced by Hutchinson–Gilford progeria syndrome. Metabolomics 15:100. https://doi.org/10.1007/s11306-019-1558-6
Hamczyk MR, Andrés V (2018) Accelerated atherosclerosis in HGPS. Aging 10:2555–2556. https://doi.org/10.18632/aging.101608
Hamczyk MR et al (2019) Progerin accelerates atherosclerosis by inducing endoplasmic reticulum stress in vascular smooth muscle cells. EMBO Molecular Medicine 11:e9736. https://doi.org/10.15252/emmm.201809736
Harhouri K et al. (2016) Antisense-based progerin downregulation in HGPS-like patients’ cells. Cells 5:31. doi:https://doi.org/10.3390/cells5030031
Harhouri K et al (2017) MG132-induced progerin clearance is mediated by autophagy activation and splicing regulation. EMBO Mol Med 9:1294–1313. https://doi.org/10.15252/emmm.201607315
Harkema L, Youssef SA, de Bruin A (2016) Pathology of mouse models of accelerated aging. Vet Pathol 53:366–389. https://doi.org/10.1177/0300985815625169
Harrison DE et al (2009) Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature 460:392–395. https://doi.org/10.1038/nature08221
Hennekam RCM (2006) Hutchinson–Gilford progeria syndrome: review of the phenotype. Am J Med Genet A 140A:2603–2624. https://doi.org/10.1002/ajmg.a.31346
Hergenreider E et al (2012) Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs. Nat Cell Biol 14:249–256. https://doi.org/10.1038/ncb2441
Hernandez L et al (2010) Functional coupling between the extracellular matrix and nuclear lamina by Wnt signaling in progeria. Dev Cell 19:413–425. https://doi.org/10.1016/j.devcel.2010.08.013
Ho JC et al (2011) Generation of induced pluripotent stem cell lines from 3 distinct laminopathies bearing heterogeneous mutations in lamin A/C. Aging 3:380–390. https://doi.org/10.18632/aging.100277
Ho Y-H et al (2019) Remodeling of bone marrow hematopoietic stem cell niches promotes myeloid cell expansion during premature or physiological aging. Cell Stem Cell 25:407–418.e406. https://doi.org/10.1016/j.stem.2019.06.007
Hu Y et al (2019) Extracellular vesicles from human umbilical cord blood ameliorate bone loss in senile osteoporotic mice. Metabolism 95:93–101. https://doi.org/10.1016/j.metabol.2019.01.009
Huang S, Chen L, Libina N, Janes J, Martin GM, Campisi J, Oshima J (2005) Correction of cellular phenotypes of Hutchinson-Gilford progeria cells by RNA interference. Hum Genet 118:444–450. https://doi.org/10.1007/s00439-005-0051-7
Ibrahim MX, Sayin VI, Akula MK, Liu M, Fong LG, Young SG, Bergo MO (2013) Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria. Science 340:1330–1333. https://doi.org/10.1126/science.1238880
Jansen F et al (2013) Endothelial microparticle–mediated transfer of microRNA-126 promotes vascular endothelial cell repair via SPRED1 and is abrogated in glucose-damaged endothelial microparticles. Circulation 128:2026–2038. https://doi.org/10.1161/CIRCULATIONAHA.113.001720
Kang HT et al (2017) Chemical screening identifies ROCK as a target for recovering mitochondrial function in Hutchinson-Gilford progeria syndrome. Aging Cell 16:541–550. https://doi.org/10.1111/acel.12584
Katsuumi G, Shimizu I, Yoshida Y, Minamino T (2018) Vascular senescence in cardiovascular and metabolic diseases. Front Cardiovasc Med 5:18–18. https://doi.org/10.3389/fcvm.2018.00018
Kawakami Y et al (2019) Rapamycin rescues age-related changes in muscle-derived stem/progenitor cells from progeroid mice. Molecular Therapy - Methods & Clinical Development 14:64–76. https://doi.org/10.1016/j.omtm.2019.05.011
Keep off-target effects in focus (2018) Nat Med 24:1081–1081. https://doi.org/10.1038/s41591-018-0150-3
Kelley JB et al (2011) The defective nuclear lamina in Hutchinson-Gilford progeria syndrome disrupts the nucleocytoplasmic Ran gradient and inhibits nuclear localization of Ubc9. Mol Cell Biol 31:3378–3395. https://doi.org/10.1128/MCB.05087-11
Kieran MW, Gordon L, Kleinman M (2007) New approaches to progeria. Pediatrics 120:834. https://doi.org/10.1542/peds.2007-1356
Kim YC, Guan K-L (2015) mTOR: a pharmacologic target for autophagy regulation. J Clin Invest 125:25–32. https://doi.org/10.1172/JCI73939
Kirkwood TBL (2005) Understanding the odd science of aging. Cell 120:437–447. https://doi.org/10.1016/j.cell.2005.01.027
Kole R, Krainer AR, Altman S (2012) RNA therapeutics: beyond RNA interference and antisense oligonucleotides. Nat Rev Drug Discov 11:125–140. https://doi.org/10.1038/nrd3625
Kreienkamp R et al (2016) Vitamin D receptor signaling improves Hutchinson-Gilford progeria syndrome cellular phenotypes. Oncotarget 7:30018–30031. https://doi.org/10.18632/oncotarget.9065
Kreienkamp R et al (2018) A cell-intrinsic interferon-like response links replication stress to cellular aging caused by progerin. Cell Rep 22:2006–2015. https://doi.org/10.1016/j.celrep.2018.01.090
Kreienkamp R et al (2019) Doubled lifespan and patient-like pathologies in progeria mice fed high-fat diet. Aging Cell 18:e12852. https://doi.org/10.1111/acel.12852
Kubben N et al (2016) Repression of the antioxidant NRF2 pathway in premature aging. Cell 165:1361–1374. https://doi.org/10.1016/j.cell.2016.05.017
Kuk MU, Kim JW, Lee Y-S, Kyung AC, Park JT, Park SC (2019) Alleviation of senescence via ATM inhibition in accelerated aging models. Mol Cells 42:210–217. https://doi.org/10.14348/molcells.2018.0352
Lainšček D, Kadunc L, Keber MM, Bratkovič IH, Romih R, Jerala R (2018) Delivery of an artificial transcription regulator dCas9-VPR by extracellular vesicles for therapeutic gene activation. ACS Synth Biol 7:2715–2725. https://doi.org/10.1021/acssynbio.8b00192
Lamichhane TN, Jay SM (2018) Production of extracellular vesicles loaded with therapeutic cargo. Methods Mol Biol 1831:37–47. https://doi.org/10.1007/978-1-4939-8661-3_4
Larrieu D, Britton S, Demir M, Rodriguez R, Jackson SP (2014) Chemical inhibition of NAT10 corrects defects of laminopathic cells. Science 344:527. https://doi.org/10.1126/science.1252651
Larrieu D, Viré E, Robson S, Breusegem SY, Kouzarides T, Jackson SP (2018) Inhibition of the acetyltransferase NAT10 normalizes progeric and aging cells by rebalancing the Transportin-1 nuclear import pathway. Sci Signal 11:eaar5401. https://doi.org/10.1126/scisignal.aar5401
Larsson O, Morita M, Topisirovic I, Alain T, Blouin M-J, Pollak M, Sonenberg N (2012) Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A 109:8977–8982. https://doi.org/10.1073/pnas.1201689109
Lavasani M et al (2012) Muscle-derived stem/progenitor cell dysfunction limits healthspan and lifespan in a murine progeria model. Nat Commun 3:608. https://doi.org/10.1038/ncomms1611 https://www.nature.com/articles/ncomms1611#supplementary-information
Lee JM et al (2016a) Modulation of LMNA splicing as a strategy to treat prelamin A diseases. J Clin Invest 126:1592–1602. https://doi.org/10.1172/JCI85908
Lee S-J et al (2016b) Interruption of progerin-lamin A/C binding ameliorates Hutchinson-Gilford progeria syndrome phenotype. J Clin Invest 126:3879–3893. https://doi.org/10.1172/JCI84164
Lewis KN, Mele J, Hayes JD, Buffenstein R (2010) Nrf2, a guardian of healthspan and gatekeeper of species longevity. Integr Comp Biol 50:829–843. https://doi.org/10.1093/icb/icq034
Li Y et al (2019) Transient introduction of human telomerase mRNA improves hallmarks of progeria cells. Aging Cell 18:e12979–e12979. https://doi.org/10.1111/acel.12979
Liao C-Y et al (2016) Rapamycin reverses metabolic deficits in lamin A/C-deficient mice. Cell Rep 17:2542–2552. https://doi.org/10.1016/j.celrep.2016.10.040
Lino CA, Harper JC, Carney JP, Timlin JA (2018) Delivering CRISPR: a review of the challenges and approaches. Drug Deliv 25:1234–1257. https://doi.org/10.1080/10717544.2018.1474964
Liu B et al (2005) Genomic instability in laminopathy-based premature aging. Nat Med 11:780. https://doi.org/10.1038/nm1266 https://www.nature.com/articles/nm1266#supplementary-information
Liu G-H et al (2011a) Recapitulation of premature ageing with iPSCs from Hutchinson–Gilford progeria syndrome. Nature 472:221. https://doi.org/10.1038/nature09879 https://www.nature.com/articles/nature09879#supplementary-information
Liu G-H et al (2011b) Targeted gene correction of laminopathy-associated LMNA mutations in patient-specific iPSCs. Cell Stem Cell 8:688–694. https://doi.org/10.1016/j.stem.2011.04.019
Liu B et al (2012) Resveratrol rescues SIRT1-dependent adult stem cell decline and alleviates progeroid features in laminopathy-based progeria. Cell Metab 16:738–750. https://doi.org/10.1016/j.cmet.2012.11.007
Liu C, Arnold R, Henriques G, Djabali K (2019a) Inhibition of JAK-STAT signaling with Baricitinib reduces inflammation and improves cellular homeostasis in progeria cells. Cells 8:1276. doi:https://doi.org/10.3390/cells8101276
Liu S, Mahairaki V, Bai H, Ding Z, Li J, Witwer KW, Cheng L (2019b) Highly purified human extracellular vesicles produced by stem cells alleviate aging cellular phenotypes of senescent human cells. Stem Cells 37:779–790. https://doi.org/10.1002/stem.2996
Lowenstein CJ, Bennett JA (2019) New vascular insights into premature aging. J Clin Invest 129:492–493. https://doi.org/10.1172/JCI125616
Lu X, Djabali K (2018) Autophagic removal of farnesylated carboxy-terminal lamin peptides. Cells 7:33. https://doi.org/10.3390/cells7040033
Lu J et al (2018) Exosomal miR-9 inhibits angiogenesis by targeting MDK and regulating PDK/AKT pathway in nasopharyngeal carcinoma. J Exp Clin Cancer Res 37:147–147. https://doi.org/10.1186/s13046-018-0814-3
Ma S et al (2016) E-selectin-targeting delivery of microRNAs by microparticles ameliorates endothelial inflammation and atherosclerosis. Sci Rep 6:22910. https://doi.org/10.1038/srep22910 https://www.nature.com/articles/srep22910#supplementary-information
Ma H et al (2017) Correction of a pathogenic gene mutation in human embryos. Nature 548:413–419. https://doi.org/10.1038/nature23305
Mannick JB et al (2014) mTOR inhibition improves immune function in the elderly. Sci Transl Med 6:268ra179–268ra179. https://doi.org/10.1126/scitranslmed.3009892
Mannick JB et al (2018) TORC1 inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med 10:eaaq1564. https://doi.org/10.1126/scitranslmed.aaq1564
Mariño G, Ugalde AP, Fernández ÁF, Osorio FG, Fueyo A, Freije JM, López-Otín C (2010) Insulin-like growth factor 1 treatment extends longevity in a mouse model of human premature aging by restoring somatotroph axis function. Proc Natl Acad Sci 107:16268–16273. https://doi.org/10.1073/pnas.1002696107
Marji J et al (2010) Defective lamin A-Rb signaling in Hutchinson-Gilford progeria syndrome and reversal by farnesyltransferase inhibition. PLoS One 5:e11132. https://doi.org/10.1371/journal.pone.0011132
Mateos J et al (2018) Next-generation sequencing and quantitative proteomics of Hutchinson-Gilford progeria syndrome-derived cells point to a role of nucleotide metabolism in premature aging. PLoS One 13:e0205878
Matrone G, Thandavarayan RA, Walther BK, Meng S, Mojiri A, Cooke JP (2019) Dysfunction of iPSC-derived endothelial cells in human Hutchinson–Gilford progeria syndrome. Cell Cycle 18:2495–2508. https://doi.org/10.1080/15384101.2019.1651587
Mattioli E et al (2019) Statins and histone deacetylase inhibitors affect lamin A/C-histone deacetylase 2 interaction in human cells. Front Cell and Dev Biol 7:6
Mayoral P, Bárcena C, López-Otín C (2018) Chapter 51—progeria mouse models. In: Ram JL, Conn PM (eds) Conn’s handbook of models for human aging (2nd Edition). Academic, pp 689–701. doi: https://doi.org/10.1016/B978-0-12-811353-0.00051-8
Mazereeuw-Hautier J, Wilson L, Mohammed S, Smallwood D, Shackleton S, Atherton D, Harper J (2007) Hutchinson–Gilford progeria syndrome: clinical findings in three patients carrying the G608G mutation in LMNA and review of the literature. Br J Dermatol 156:1308–1314. https://doi.org/10.1111/j.1365-2133.2007.07897.x
McKenna TS, Baek J-H, Eriksson M (2013) Laminopathies. In: Puiu M (ed) Genetic disorders. IntechOpen Limited, London, pp 27–64. https://doi.org/10.5772/53793
Mehta IS, Eskiw CH, Arican HD, Kill IR, Bridger JM (2011) Farnesyltransferase inhibitor treatment restores chromosome territory positions and active chromosome dynamics in Hutchinson-Gilford progeria syndrome cells. Genome Biol 12:R74. https://doi.org/10.1186/gb-2011-12-8-r74
Mendt M et al (2018) Generation and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight 3. https://doi.org/10.1172/jci.insight.99263
Merideth MA et al (2008) Phenotype and course of Hutchinson–Gilford progeria syndrome. N Engl J Med 358:592–604. https://doi.org/10.1056/NEJMoa0706898
Miller RA et al (2011) Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol: Series A 66:191–201. https://doi.org/10.1093/gerona/glq178
Miller RA et al (2014) Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell 13:468–477. https://doi.org/10.1111/acel.12194
Mistriotis P et al (2017) NANOG reverses the myogenic differentiation potential of senescent stem cells by restoring actin filamentous organization and SRF-dependent gene expression. Stem Cells 35:207–221. https://doi.org/10.1002/stem.2452
Mizushima N, Komatsu M (2011) Autophagy: renovation of cells and tissues. Cell 147:728–741. https://doi.org/10.1016/j.cell.2011.10.026
Moulson CL, Go G, Gardner JM, van der Wal AC, Smitt JHS, van Hagen JM, Miner JH (2005) Homozygous and compound heterozygous mutations in ZMPSTE24 cause the laminopathy restrictive dermopathy. J Investig Dermatol 125:913–919. https://doi.org/10.1111/j.0022-202X.2005.23846.x
Mueller MA, Beutner F, Teupser D, Ceglarek U, Thiery J (2008) Prevention of atherosclerosis by the mTOR inhibitor everolimus in LDLR−/− mice despite severe hypercholesterolemia. Atherosclerosis 198:39–48. https://doi.org/10.1016/j.atherosclerosis.2007.09.019
Murphy DE, de Jong OG, Brouwer M, Wood MJ, Lavieu G, Schiffelers RM, Vader P (2019) Extracellular vesicle-based therapeutics: natural versus engineered targeting and trafficking. Exp Mol Med 51:32. https://doi.org/10.1038/s12276-019-0223-5
Nair V, Sreevalsan S, Basha R, Abdelrahim M, Abudayyeh A, Hoffman AR, Safe S (2014) Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors. J Biol Chem 289:27692–27701. https://doi.org/10.1074/jbc.M114.592576
Nassar W et al (2016) Umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res 20:21–21. https://doi.org/10.1186/s40824-016-0068-0
Navarro CL et al (2004) Lamin A and ZMPSTE24 (FACE-1) defects cause nuclear disorganization and identify restrictive dermopathy as a lethal neonatal laminopathy. Hum Mol Genet 13:2493–2503. https://doi.org/10.1093/hmg/ddh265
Navarro CL et al (2005) Loss of ZMPSTE24 (FACE-1) causes autosomal recessive restrictive dermopathy and accumulation of lamin A precursors. Hum Mol Genet 14:1503–1513. https://doi.org/10.1093/hmg/ddi159
Navarro CL et al (2014) New ZMPSTE24 (FACE1) mutations in patients affected with restrictive dermopathy or related progeroid syndromes and mutation update. Eur J Hum Genet 22:1002. https://doi.org/10.1038/ejhg.2013.258
Nissan X, Blondel S, Peschanski M (2011) In vitro pathological modelling using patient-specific induced pluripotent stem cells: the case of progeria, vol vol 39. Portland Press Limited. https://doi.org/10.1042/BST20110659
Nissan X et al (2012) Unique preservation of neural cells in Hutchinson-Gilford progeria syndrome is due to the expression of the neural-specific miR-9 microRNA. Cell Rep 2:1–9. https://doi.org/10.1016/j.celrep.2012.05.015
Ocampo A et al (2016) In vivo amelioration of age-associated hallmarks by partial reprogramming. Cell 167:1719–1733. e1712. https://doi.org/10.1016/j.cell.2016.11.052
Osorio FG et al (2011) Splicing-directed therapy in a new mouse model of human accelerated aging. Sci Transl Med 3:106ra107–106ra107. https://doi.org/10.1126/scitranslmed.3002847
Osorio FG et al (2012) Nuclear lamina defects cause ATM-dependent NF-κB activation and link accelerated aging to a systemic inflammatory response. Genes Dev 26:2311–2324. https://doi.org/10.1101/gad.197954.112
Ovadya Y et al (2018) Impaired immune surveillance accelerates accumulation of senescent cells and aging. Nat Commun 9:5435. https://doi.org/10.1038/s41467-018-07825-3
Pacheco LM, Gomez LA, Dias J, Ziebarth NM, Howard GA, Schiller PC (2014) Progerin expression disrupts critical adult stem cell functions involved in tissue repair. Aging (Albany NY) 6:1049. https://doi.org/10.18632/aging.100709
Panagiotou N, Neytchev O, Selman C, Shiels PG (2018) Extracellular vesicles, ageing, and therapeutic interventions. Cells 7:110. https://doi.org/10.3390/cells7080110
Park SK, Shin OS (2017) Metformin alleviates ageing cellular phenotypes in Hutchinson–Gilford progeria syndrome dermal fibroblasts. Exp Dermatol 26:889–895. https://doi.org/10.1111/exd.13323
Park JT, Kang HT, Park CH, Lee Y-S, Cho KA, Park SC (2018) A crucial role of ROCK for alleviation of senescence-associated phenotype. Exp Gerontol 106:8–15. https://doi.org/10.1016/j.exger.2018.02.012
Park K-S, Bandeira E, Shelke GV, Lässer C, Lötvall J (2019) Enhancement of therapeutic potential of mesenchymal stem cell-derived extracellular vesicles. Stem Cell Res Ther 10:288. https://doi.org/10.1186/s13287-019-1398-3
Pegoraro G, Kubben N, Wickert U, Göhler H, Hoffmann K, Misteli T (2009) Ageing-related chromatin defects through loss of the NURD complex. Nat Cell Biol 11:1261. https://doi.org/10.1038/ncb1971
Pellegrini C et al (2015) All-trans retinoic acid and rapamycin normalize Hutchinson Gilford progeria fibroblast phenotype. Oncotarget 6:29914. https://doi.org/10.18632/oncotarget.4939
Pendás AM et al (2002) Defective prelamin A processing and muscular and adipocyte alterations in Zmpste24 metalloproteinase–deficient mice. Nat Genet 31:94–99. https://doi.org/10.1038/ng871
Petrini S et al (2017) Aged induced pluripotent stem cell (iPSCs) as a new cellular model for studying premature aging. Aging (Albany NY) 9:1453. https://doi.org/10.18632/aging.101248
Piekarowicz K, Machowska M, Dzianisava V, Rzepecki R (2019) Hutchinson-Gilford progeria syndrome—current status and prospects for gene therapy treatment. Cells 8:88. https://doi.org/10.3390/cells8020088
Qian M et al (2018) Boosting ATM activity alleviates aging and extends lifespan in a mouse model of progeria. eLife 7:e34836. https://doi.org/10.7554/eLife.34836
Rajawat Y, Hilioti Z, Bossis I (2010) Autophagy: a target for retinoic acids. Autophagy 6:1224–1226. https://doi.org/10.4161/auto.6.8.13793
Rajawat Y, Hilioti Z, Bossis I (2011) Retinoic acid induces autophagosome maturation through redistribution of the cation-independent mannose-6-phosphate receptor. Antioxid Redox Signal 14:2165–2177. https://doi.org/10.1089/ars.2010.3491
Ramos FJ et al (2012) Rapamycin reverses elevated mTORC1 signaling in lamin A/C–deficient mice, rescues cardiac and skeletal muscle function, and extends survival. Sci Transl Med 4:144ra103–144ra103. https://doi.org/10.1126/scitranslmed.3003802
Reiner AT et al (2017) Concise review: Developing best-practice models for the therapeutic use of extracellular vesicles. Stem Cells Transl Med 6:1730–1739. https://doi.org/10.1002/sctm.17-0055
Ribas J et al (2017) Biomechanical strain exacerbates inflammation on a progeria-on-a-chip model. Small 13:1603737. https://doi.org/10.1002/smll.201603737
Richards SA, Muter J, Ritchie P, Lattanzi G, Hutchison CJ (2011) The accumulation of un-repairable DNA damage in laminopathy progeria fibroblasts is caused by ROS generation and is prevented by treatment with N-acetyl cysteine. Hum Mol Genet 20:3997–4004. https://doi.org/10.1093/hmg/ddr327
Rivera-Torres J et al (2013) Identification of mitochondrial dysfunction in Hutchinson–Gilford progeria syndrome through use of stable isotope labeling with amino acids in cell culture. J Proteome 91:466–477. https://doi.org/10.1016/j.jprot.2013.08.008
Roballo KCS et al (2019) Neurons-derived extracellular vesicles promote neural differentiation of ADSCs: a model to prevent peripheral nerve degeneration. Sci Rep 9:11213–11213. https://doi.org/10.1038/s41598-019-47229-x
Robbins PD (2017) Extracellular vesicles and aging. Stem Cell Investigation 4:98. https://doi.org/10.21037/sci.2017.12.03
Rong N et al (2019) Restoring extracellular matrix synthesis in senescent stem cells. FASEB J 201900377R. https://doi.org/10.1096/fj.201900377R
Roos CM et al (2016) Chronic senolytic treatment alleviates established vasomotor dysfunction in aged or atherosclerotic mice. Aging Cell 15:973–977. https://doi.org/10.1111/acel.12458
Rork JF, Huang JT, Gordon LB, Kleinman M, Kieran MW, Liang MG (2014) Initial cutaneous manifestations of Hutchinson-Gilford progeria syndrome. Pediatr Dermatol 31:196–202. https://doi.org/10.1111/pde.12284
Rosengardten Y, McKenna T, Grochová D, Eriksson M (2011) Stem cell depletion in Hutchinson–Gilford progeria syndrome. Aging Cell 10:1011–1020. https://doi.org/10.1111/j.1474-9726.2011.00743.x
Russell SJ, Kahn CR (2007) Endocrine regulation of ageing. Nat Rev Mol Cell Biol 8:681–691. https://doi.org/10.1038/nrm2234
Sagelius H, Rosengardten Y, Schmidt E, Sonnabend C, Rozell B, Eriksson M (2008) Reversible phenotype in a mouse model of Hutchinson–Gilford progeria syndrome. J Med Genet 45:794–801. https://doi.org/10.1136/jmg.2008.060772
Santiago-Fernández O et al (2019) Development of a CRISPR/Cas9-based therapy for Hutchinson–Gilford progeria syndrome. Nat Med 25:423–426. https://doi.org/10.1038/s41591-018-0338-6
Scaffidi P, Misteli T (2005) Reversal of the cellular phenotype in the premature aging disease Hutchinson-Gilford progeria syndrome. Nat Med 11:440–445. https://doi.org/10.1038/nm1204
Scaffidi P, Misteli T (2006) Lamin A-dependent nuclear defects in human aging. Science 312:1059–1063. https://doi.org/10.1126/science.1127168
Scaffidi P, Misteli T (2008) Lamin A-dependent misregulation of adult stem cells associated with accelerated ageing. Nat Cell Biol 10:452–459. https://doi.org/10.1038/ncb1708
Serebryannyy L, Misteli T (2018) Protein sequestration at the nuclear periphery as a potential regulatory mechanism in premature aging. J Cell Biol 217:21–37. https://doi.org/10.1083/jcb.201706061
Settembre C, Fraldi A, Medina DL, Ballabio A (2013) Signals from the lysosome: a control centre for cellular clearance and energy metabolism. Nat Rev Mol Cell Biol 14:283. https://doi.org/10.1038/nrm3565
Shumaker DK et al (2006) Mutant nuclear lamin A leads to progressive alterations of epigenetic control in premature aging. Proc Natl Acad Sci 103:8703–8708. https://doi.org/10.1073/pnas.0602569103
Sieprath T et al (2015) Sustained accumulation of prelamin A and depletion of lamin A/C both cause oxidative stress and mitochondrial dysfunction but induce different cell fates. Nucleus 6:236–246. https://doi.org/10.1080/19491034.2015.1050568
Sil S, Dagur RS, Liao K, Peeples ES, Hu G, Periyasamy P, Buch S (2019) Strategies for the use of extracellular vesicles for the delivery of therapeutics. J NeuroImmune Pharmacol. https://doi.org/10.1007/s11481-019-09873-y
Sinha JK, Ghosh S, Raghunath M (2014) Progeria: a rare genetic premature ageing disorder. Indian J Med Res 139:667
Spear ED et al (2019) A humanized yeast system to analyze cleavage of prelamin A by ZMPSTE24. Methods 157:47–55. https://doi.org/10.1016/j.ymeth.2019.01.001
Strandgren C et al (2015) Transgene silencing of the Hutchinson-Gilford progeria syndrome mutation results in a reversible bone phenotype, whereas resveratrol treatment does not show overall beneficial effects. FASEB J 29:3193–3205. https://doi.org/10.1096/fj.14-269217
Tilstra JS, Clauson CL, Niedernhofer LJ, Robbins PD (2011) NF-κB in aging and disease. Aging Dis 2:449
Tilstra JS et al (2012) NF-κB inhibition delays DNA damage–induced senescence and aging in mice. J Clin Invest 122:2601–2612. https://doi.org/10.1172/JCI45785
Toth JI et al (2005) Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes. Proc Natl Acad Sci 102:12873–12878
Ullrich NJ, Gordon LB (2015) Chapter 18—Hutchinson–Gilford progeria syndrome. In: Islam MP, Roach ES (eds) Handbook of clinical neurology, vol vol 132. Elsevier, pp 249–264. https://doi.org/10.1016/B978-0-444-62702-5.00018-4
Ullrich NJ et al (2013) Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. Neurology 81:427–430. https://doi.org/10.1212/WNL.0b013e31829d85c0
van Niel G, D'Angelo G, Raposo G (2018) Shedding light on the cell biology of extracellular vesicles. Nat Rev Mol Cell Biol 19:213–228. https://doi.org/10.1038/nrm.2017.125
Varela I et al (2008) Combined treatment with statins and aminobisphosphonates extends longevity in a mouse model of human premature aging. Nat Med 14:767–772. https://doi.org/10.1038/nm1786
Varga R et al (2006) Progressive vascular smooth muscle cell defects in a mouse model of Hutchinson-Gilford progeria syndrome. Proc Natl Acad Sci U S A 103:3250–3255. https://doi.org/10.1073/pnas.0600012103
Vellai T, Takacs-Vellai K, Zhang Y, Kovacs AL, Orosz L, Müller F (2003) Influence of TOR kinase on lifespan in C. elegans. Nature 426:620. https://doi.org/10.1038/426620a
Verstraeten V, Broers J, Ramaekers F, van Steensel M (2007) The nuclear envelope, a key structure in cellular integrity and gene expression. Curr Med Chem 14:1231–1248. https://doi.org/10.2174/092986707780598032
Vidak S, Foisner R (2016) Molecular insights into the premature aging disease progeria. Histochem Cell Biol 145:401–417. https://doi.org/10.1007/s00418-016-1411-1
Vidak S, Kubben N, Dechat T, Foisner R (2015) Proliferation of progeria cells is enhanced by lamina-associated polypeptide 2α (LAP2α) through expression of extracellular matrix proteins. Genes Dev 29:2022–2036. https://doi.org/10.1101/gad.263939.115
Villa F, Quarto R, Tasso R (2019) Extracellular vesicles as natural, safe and efficient drug delivery systems. Pharmaceutics 11:557. https://doi.org/10.3390/pharmaceutics11110557
Villa-Bellosta R, Rivera-Torres J, Osorio FG, Acín-Pérez R, Enriquez JA, López-Otín C, Andrés V (2013) Defective extracellular pyrophosphate metabolism promotes vascular calcification in a mouse model of Hutchinson-Gilford progeria syndrome that is ameliorated on pyrophosphate treatment. Circulation 127:2442–2451. https://doi.org/10.1161/CIRCULATIONAHA.112.000571
Waksman R et al (2003) Oral rapamycin inhibits growth of atherosclerotic plaque in apoE knock-out mice. Cardiovasc Radiat Med 4:34–38. https://doi.org/10.1016/S1522-1865(03)00121-5
Wang Y et al (2016) A mutation abolishing the ZMPSTE24 cleavage site in prelamin A causes a progeroid disorder. J Cell Sci 129:1975–1980. https://doi.org/10.1242/jcs.187302
Xiong ZM et al (2016) Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria. Aging Cell 15:279–290. https://doi.org/10.1111/acel.12434
Xiong Z-M, O’Donovan M, Sun L, Choi JY, Ren M, Cao K (2017) Anti-aging potentials of methylene blue for human skin longevity. Sci Rep 7:2475. https://doi.org/10.1038/s41598-017-02419-3
Yang SH et al (2005) Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson–Gilford progeria syndrome mutation. Proc Natl Acad Sci 102:10291–10296
Yang SH et al (2006) A farnesyltransferase inhibitor improves disease phenotypes in mice with a Hutchinson-Gilford progeria syndrome mutation. J Clin Invest 116:2115–2121. https://doi.org/10.1172/JCI28968
Yang SH, Andres DA, Spielmann HP, Young SG, Fong LG (2008a) Progerin elicits disease phenotypes of progeria in mice whether or not it is farnesylated. J Clin Invest 118:3291–3300. https://doi.org/10.1172/JCI35876
Yang SH, Qiao X, Fong LG, Young SG (2008b) Treatment with a farnesyltransferase inhibitor improves survival in mice with a Hutchinson–Gilford progeria syndrome mutation. Biochimica et Biophysica Acta (BBA)-Molecular and Cell Biology of Lipids 1781:36–39. https://doi.org/10.1016/j.bbalip.2007.11.003
Yang SH et al (2011) Absence of progeria-like disease phenotypes in knock-in mice expressing a non-farnesylated version of progerin. Hum Mol Genet 20:436–444. https://doi.org/10.1093/hmg/ddq490
Yang L et al (2018) Exosomal miR-9 released from HIV tat stimulated astrocytes mediates microglial migration. J NeuroImmune Pharmacol 13:330–344. https://doi.org/10.1007/s11481-018-9779-4
Yang L, Zhu J, Zhang C, Wang J, Yue F, Jia X, Liu H (2019) Stem cell-derived extracellular vesicles for myocardial infarction: a meta-analysis of controlled animal studies. Aging 11:1129–1150. https://doi.org/10.18632/aging.101814
Yong-Fu L (2016) In vivo delivery of morpholino oligos as therapeutics: what barriers still exist? Journal of Drug Discovery Development and Delivery 3:1017
Yosef R et al (2016) Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL. Nat Commun 7:11190. https://doi.org/10.1038/ncomms11190
Yoshida M et al. (2019) Extracellular vesicle-contained eNAMPT delays aging and extends lifespan in mice. Cell Metabolism 30:329–342.e325. doi: https://doi.org/10.1016/j.cmet.2019.05.015
Young SG, Yang SH, Davies BS, Jung H-J, Fong LG (2013) Targeting protein prenylation in progeria. Sci Transl Med 5:171ps173–171ps173. https://doi.org/10.1126/scitranslmed.3005229
Yuan H-X, Russell RC, Guan K-L (2013) Regulation of PIK3C3/VPS34 complexes by MTOR in nutrient stress-induced autophagy. Autophagy 9:1983–1995. https://doi.org/10.4161/auto.26058
Yuan F-L et al (2018) Osteoclast-derived extracellular vesicles: novel regulators of osteoclastogenesis and osteoclast–osteoblasts communication in bone remodeling. Front Physiol 9:628. https://doi.org/10.3389/fphys.2018.00628
Zernecke A et al (2009) Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2:ra81. https://doi.org/10.1126/scisignal.2000610
Zhang J et al (2011) A human iPSC model of Hutchinson Gilford progeria reveals vascular smooth muscle and mesenchymal stem cell defects. Cell Stem Cell 8:31–45. https://doi.org/10.1016/j.stem.2010.12.002
Zhang Y et al (2013) Rapamycin extends life and health in C57BL/6 mice. J Gerontol A: Biomed Sci Medi Sci 69:119–130. https://doi.org/10.1093/gerona/glt056
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
ESM 1
(PDF 263 kb)
About this article
Cite this article
Saxena, S., Kumar, S. Pharmacotherapy to gene editing: potential therapeutic approaches for Hutchinson–Gilford progeria syndrome. GeroScience 42, 467–494 (2020). https://doi.org/10.1007/s11357-020-00167-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11357-020-00167-3